Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) CFO Jason Haas purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $20,000.00. Following the completion of the transaction, the chief financial officer directly owned 62,908 shares in the company, valued at $1,258,160. This trade represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Odyssey Therapeutics Stock Performance
NASDAQ ODTX traded up $1.03 during trading on Monday, reaching $17.45. 426,992 shares of the stock traded hands. Odyssey Therapeutics, Inc. has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.
Recommended Stories
- Five stocks we like better than Odyssey Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
